| Autor: |
Durrani, Misbah, Durrani, Jahanzeb, ul Haq, Inam, Inam, Zainab |
| Předmět: |
|
| Zdroj: |
Ophthalmology Update; Oct-Dec2020, Vol. 18 Issue 4, p36-39, 4p |
| Abstrakt: |
Background Coronavirus disease is associated with diffuse lung damage. Glucocorticoids may modulate inflammationmediated lung injury leading to respiratory complications and death. Methods. In this controlled study, possible treatments in patients who were hospitalized with Covid-19, patients were randomly assigned to receive oral or intravenous dexamethasone (at a normal dose daily) for up to 10 days or to receive usual care alone. Here, we report the preliminary results of this comparison. Results A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization. The mortality varied considerably according to the level of respiratory support patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation and among those receiving oxygen without invasive mechanical ventilation but not among those who were receiving no respiratory support at randomization. Conclusions. In patients hospitalized with Covid-19, the use of dexamethasone resulted in lowered 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
